<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36987605</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>Dilemma of immunosuppression and infection risk in systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>i22</StartPage><EndPage>i29</EndPage><MedlinePgn>i22-i29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keac678</ELocationID><Abstract><AbstractText>Patients with SLE are at high risk of various infections as evidenced by a number of studies. The main determinants of infection in SLE are disease activity, organ damage, and often inevitable medication. The molecular and cellular mechanisms underlying infection remain unclear. Impaired immunity, immunosuppressants and corticosteroids clearly increase the risk of infection, whereas some medications, such as low-dose IL-2, hydroxychloroquine and IVIG are safe in SLE patients with substantial evidence. It is important to balance the immunosuppression and infection risks in practice. This article focuses on medication-related infections in SLE and discusses the therapeutic options for the disease in clinical practice.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3904-8928</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhanguo</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-2590-6242</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007239" MajorTopicYN="Y">Infections</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">immunosuppressive therapy</Keyword><Keyword MajorTopicYN="N">infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36987605</ArticleId><ArticleId IdType="pmc">PMC10050939</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keac678</ArticleId><ArticleId IdType="pii">7087229</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldblatt F, Chambers S, Rahman A, Isenberg DA.. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009;18:682&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19502263</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X, Zou Y, Pan W. et al. Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus. Lupus 2014;23:327&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">24297642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I. et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009;11:R109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745791</ArticleId><ArticleId IdType="pubmed">19604357</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz MB, Gladman DD, Farewell V. et al. Accrual of atherosclerotic vascular events in a multicenter inception systemic lupus erythematosus cohort. Arthritis Rheumatol 2020;72:1734&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">32515554</ArticleId></ArticleIdList></Reference><Reference><Citation>Odendahl M, Jacobi A, Hansen A. et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11067960</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaipl US, Brunner J, Beyer TD. et al. Disposal of dying cells: a balancing act between infection and autoimmunity. Arthritis Rheum 2003;48:6&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12528098</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsson PE, Forslund E, Vanherberghen B. et al. Distinct migration and contact dynamics of resting and IL-2-activated human natural killer cells. Front Immunol 2014;5:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945532</ArticleId><ArticleId IdType="pubmed">24639676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 2020;21:605&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135909</ArticleId><ArticleId IdType="pubmed">32367037</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Zhang R, Shao M. et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2020;79:141&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937406</ArticleId><ArticleId IdType="pubmed">31537547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhearn B, Bruce IN.. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford) 2015;54:383&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334686</ArticleId><ArticleId IdType="pubmed">25406359</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrezenmeier E, D&#xf6;rner T.. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich JY, Cacoub P, Rosenzwajg M. et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis 2022;81:1685&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">35973803</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Khamashta MA, Font J. et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">14530779</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang Y, Zhu R. et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Medicine (Baltimore) 2015;94:e794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4603034</ArticleId><ArticleId IdType="pubmed">25929930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Chen J, He J. et al. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. PLoS Pathog 2021;17:e1009858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8525737</ArticleId><ArticleId IdType="pubmed">34618873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose NR. The role of infection in the pathogenesis of autoimmune disease. Semin Immunol 1998;10:5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9529651</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am 2006;20:849&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">17118293</ArticleId></ArticleIdList></Reference><Reference><Citation>Illescas-Montes R, Corona-Castro CC, Melguizo-Rodr&#xed;guez L, Ruiz C, Costela-Ruiz VJ.. Infectious processes and systemic lupus erythematosus. Immunology 2019;158:153&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6797874</ArticleId><ArticleId IdType="pubmed">31386190</ArticleId></ArticleIdList></Reference><Reference><Citation>Doaty S, Agrawal H, Bauer E, Furst DE.. Infection and lupus: which causes which? Curr Rheumatol Rep 2016;18:13.</Citation><ArticleIdList><ArticleId IdType="pubmed">26951251</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews SF, Huang Y, Kaur K. et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med 2015;7:316ra192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4770855</ArticleId><ArticleId IdType="pubmed">26631631</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton BR, Tennant RK, Love J. et al. Variant proteins stimulate more IgM+ GC B-cells revealing a mechanism of cross-reactive recognition by antibody memory. eLife 2018;7:e26832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5959717</ArticleId><ArticleId IdType="pubmed">29709214</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquart HV, Svendsen A, Rasmussen JM. et al. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995;101:60&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1553287</ArticleId><ArticleId IdType="pubmed">7621593</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber MRW, Clarke AE.. Systemic lupus erythematosus and risk of infection. Expert Rev Clin Immunol 2020;16:527&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">32478627</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts MB, Fishman JA.. Immunosuppressive agents and infectious risk in transplantation: managing the &#x2018;Net State of Immunosuppression&#x2019;. Clin Infect Dis 2021;73:e1302&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8561260</ArticleId><ArticleId IdType="pubmed">32803228</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Furie R.. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393:2344&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang I, Park SH.. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003;15:528&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960476</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrinton LJ, Liu L, Goldfien R, Michaels MA, Tran TN.. Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials. J Rheumatol 2016;43:1503&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27370880</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB. et al. Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort. Lupus 2019;28:1101&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">31291843</ArticleId></ArticleIdList></Reference><Reference><Citation>Drosos GC, Vedder D, Houben E. et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2022;81:768&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">35110331</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Hossain A, Kotb A, Wells G.. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med 2016;14:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5022202</ArticleId><ArticleId IdType="pubmed">27623861</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Zhang H, Peng X. et al. Effect of tacrolimus vs intravenous cyclophosphamide on complete or partial response in patients with lupus nephritis: a randomized clinical trial. JAMA Netw Open 2022;5:e224492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8969066</ArticleId><ArticleId IdType="pubmed">35353167</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao M, Miao M, Zhang X. et al. Comparison of short interval and low dose with high dose of intravenous cyclophosphamide in the susceptibility of infection in patients with SLE: a multicentcentre, real-world study from China. Lupus Sci Med 2022;9:e000779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9644361</ArticleId><ArticleId IdType="pubmed">36351697</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel GB, Contreras G, Dooley MA. et al.; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678035</ArticleId><ArticleId IdType="pubmed">19369404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooley MA, Jayne D, Ginzler EM. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">22087680</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Ying KY, Yim CW. et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 2016;75:30&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25550339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fervenza FC, Appel GB, Barbour SJ, MENTOR Investigators et al.Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019;381:36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">31269364</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Doria A, Mosca M. et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">17699309</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Teng YKO, Ginzler EM. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021;397:2070&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Qi C, Zha Y. et al. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. Clin Rheumatol 2019;38:859&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">30426311</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui TG, Hou FF, Ni ZH. et al. Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multi-center controlled clinical trial. Zhonghua Nei Ke Za Zhi 2005;44:672&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16202258</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W, Gomez-Reino J, Olech E. et al. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis 2012;71:1289&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396459</ArticleId><ArticleId IdType="pubmed">22307942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai R, Honda S, Tanaka E. et al. The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine. Lupus 2020;29:1712&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32838624</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Neuwelt CM, Wallace DJ. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Furie R, Latinis K. et al.; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Bae SC, Bass D. et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 2018;77:355&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867402</ArticleId><ArticleId IdType="pubmed">29295825</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Shanahan WR, Scheinberg M. et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2018;77:883&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29563108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysler EF, Spindler AJ, Guzman R. et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013;65:2368&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">23740801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia YL, Zhang J, Tummala R. et al. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2022;61:1900&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9071514</ArticleId><ArticleId IdType="pubmed">34528084</ArticleId></ArticleIdList></Reference><Reference><Citation>Yee CS, Gordon C, Dostal C. et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004;63:525&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1755006</ArticleId><ArticleId IdType="pubmed">15082482</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, Illei GG, Braun MJ, Balow JE.. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663831</ArticleId><ArticleId IdType="pubmed">19297556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannah J, Casian A, D&#x2019;Cruz D.. Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun Rev 2016;15:93&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">26427983</ArticleId></ArticleIdList></Reference><Reference><Citation>Juvvadi PR, Fox D, Bobay BG. et al. Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents. Nat Commun 2019;10:4275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753081</ArticleId><ArticleId IdType="pubmed">31537789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Lee KT, Lee SJ. et al. In vitro and in vivo assessment of FK506 analogs as novel antifungal drug candidates. Antimicrob Agents Chemother 2018;62:e01627-18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6201060</ArticleId><ArticleId IdType="pubmed">30181374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Furie RA, Tanaka Y. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:222&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30043749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraaij T, Arends EJ, van Dam LS. et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant 2021;36:1474&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8311580</ArticleId><ArticleId IdType="pubmed">32591783</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Wallace DJ, Wax S. et al.; ADDRESS II Investigators. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, Phase IIb study. Arthritis Rheumatol 2018;70:266&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099253</ArticleId><ArticleId IdType="pubmed">29073347</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y. et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, O&#x2019;Dwyer T, Petri M.. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 2019;393:2332&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Liu J, Wang Y. et al. Immunotherapy using IL-2 and GM-CSF is a potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci China Life Sci 2012;55:800&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Huang D, Yao S. et al. IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB. J Immunol 2012;188:4278&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412415</ArticleId><ArticleId IdType="pubmed">22474020</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihei J, Cardillo F, Mengel J.. The blockade of interleukin-2 during the acute phase of Trypanosoma cruzi infection reveals its dominant regulatory role. Front Cell Infect Microbiol 2021;11:758273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8635756</ArticleId><ArticleId IdType="pubmed">34869064</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Honma S, Abe S, Tamura H.. Effects of interleukin-2 and cyclosporin A on pathologic features in Mycoplasma pneumonia. Am J Respir Crit Care Med 1996;154:1908&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970385</ArticleId></ArticleIdList></Reference><Reference><Citation>von Spee-Mayer C, Siegert E, Abdirama D. et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis 2016;75:1407&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26324847</ArticleId></ArticleIdList></Reference><Reference><Citation>Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM.. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994;344:856&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7916403</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadoun D, Rosenzwajg M, Joly F. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">22129253</ArticleId></ArticleIdList></Reference><Reference><Citation>Rempenault C, Combe B, Barnetche T. et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2018;77:98&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">28970215</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A, Petri M.. Systemic lupus erythematosus: diagnosis and clinical management. J Autoimmun 2019;96:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao W, Lin JX, Leonard WJ.. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013;38:13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3610532</ArticleId><ArticleId IdType="pubmed">23352221</ArticleId></ArticleIdList></Reference><Reference><Citation>Vachino G, Gelfand JA, Atkins MB. et al. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 1991;78:2505&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">1824247</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijs LG, Hack CE, Strack van Schijndel RJ. et al. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol 1990;144:2419&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">2313099</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannick JB, Morris M, Hockey HUP. et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 2018;10:eaaq1564.</Citation><ArticleIdList><ArticleId IdType="pubmed">29997249</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber SM, Levitz SM.. Chloroquine antagonizes the proinflammatory cytokine response to opportunistic fungi by alkalizing the fungal phagolysosome. J Infect Dis 2001;183:935&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237811</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zhu X, Ji X. et al. Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine 2017;24:189&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5652284</ArticleId><ArticleId IdType="pubmed">29033372</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo SJ, Liu DX, Kim HS, Park H.. Anti-malarial effect of novel chloroquine derivatives as agents for the treatment of malaria. Malar J 2017;16:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316213</ArticleId><ArticleId IdType="pubmed">28212631</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993;23:82&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8278823</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Yi C, Li C. et al. Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus. Antiviral Res 2019;169:104547.</Citation><ArticleIdList><ArticleId IdType="pubmed">31251958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan KM, Kopecky KJ, Jocom J. et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323:705&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">2167452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazeraud A, Jamme M, Mancusi RL. et al. Intravenous immunoglobulins in patients with COVID-19&#x2013;associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2022;10:158&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8585489</ArticleId><ArticleId IdType="pubmed">34774185</ArticleId></ArticleIdList></Reference><Reference><Citation>Benotmane I, Solis M, Velay A. et al. Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV&#x2010;associated nephropathy in kidney transplant recipients&#x2014;results from a proof&#x2010;of&#x2010;concept study. Am. J. Transplant 2021;21:329&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">32741096</ArticleId></ArticleIdList></Reference><Reference><Citation>Brocklehurst P, Farrell B, King A. et al.; INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011;365:1201&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21962214</ArticleId></ArticleIdList></Reference><Reference><Citation>Atluri S, Manchikanti L, Hirsch JA.. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician 2020;23:E71&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">32214286</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy H, Kuok DIT, Hui KPY. et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1) virus-associated acute lung injury. J Infect Dis 2019;219:186&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6306016</ArticleId><ArticleId IdType="pubmed">30085072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Huang S, Yuan X. et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol 2017;14:423&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5423084</ArticleId><ArticleId IdType="pubmed">26435067</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZG, Mu R, Dai ZP, Gao XM.. T cell vaccination in systemic lupus erythematosus with autologous activated T cells. Lupus 2005;14:884&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16335580</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>